文献速递肿瘤 PET/CT核素与放射性配体治疗

食管鳞状细胞癌模型中64Cu/177Lu标记抗表皮生长因子受体抗体的累积活度比较

Cumulated Activity Comparison of 64Cu-/177Lu-Labeled Anti-Epidermal Growth Factor Receptor Antibody in Esophageal Squamous Cell Carcinoma Model.
PubMed 文献 · J Nucl Med · 2017-01-12

本研究在小鼠食管鳞状细胞癌模型中,对已发表的64Cu-西妥昔单抗免疫PET和177Lu-西妥昔单抗小动物SPECT/CT生物分布数据进行动力学模型分析,估算摄取速率K、释放速率常数kR及累积活度AC。结果显示64Cu/177Lu-西妥昔单抗的K分别为0.0566/0.0593 g·h⁻¹·g⁻¹,kR分别为0.0150/0.0030 h⁻¹,AC分别为2.3×10¹⁰/4.1×10¹²(每克TE-8肿瘤),注射活度分别为3.70/12.95 MBq。结论认为该模型可用于比较伴随诊断/治疗性64Cu/177Lu-西妥昔单抗的动力学参数和累积活度,作者认为这可能是确定能否真正用前者预测后者剂量学的步骤。

要点

  • 模型估算了64Cu/177Lu-西妥昔单抗的K分别为0.0566/0.0593 g·h⁻¹·g⁻¹。
  • kR分别为0.0150/0.0030 h⁻¹,AC分别为2.3×10¹⁰/4.1×10¹²(每克TE-8肿瘤)。
  • 作者认为该模型可能是用诊断性64Cu预测治疗性177Lu剂量学的步骤。

核心结论

  • 作者认为该模型可用于比较伴随诊断/治疗性64Cu/177Lu-西妥昔单抗的动力学参数和累积活度,并可能是确定能否真正用前者预测后者剂量学的步骤。

研究设计与样本

  • 在荷食管鳞状细胞癌肿瘤小鼠中,对已发表的64Cu-西妥昔单抗免疫PET和177Lu-西妥昔单抗小动物SPECT/CT生物分布数据(包括血液和TE-8肿瘤)应用动力学模型分析,估算摄取K、释放速率常数kR及累积活度AC。

主要发现

  • 64Cu/177Lu-西妥昔单抗的K分别为0.0566/0.0593 g·h⁻¹·g⁻¹,kR分别为0.0150/0.0030 h⁻¹。
  • 64Cu/177Lu-西妥昔单抗的AC分别为2.3×10¹⁰/4.1×10¹²(每克TE-8肿瘤),注射活度分别为3.70/12.95 MBq。

关键数值与推荐

  • 64Cu-西妥昔单抗:K 0.0566 g·h⁻¹·g⁻¹,kR 0.0150 h⁻¹,AC 2.3×10¹⁰(每克TE-8肿瘤),注射活度3.70 MBq。
  • 177Lu-西妥昔单抗:K 0.0593 g·h⁻¹·g⁻¹,kR 0.0030 h⁻¹,AC 4.1×10¹²(每克TE-8肿瘤),注射活度12.95 MBq。

临床怎么用

  • 作者认为该模型可能是确定能否真正用诊断性64Cu-西妥昔单抗预测治疗性177Lu-西妥昔单抗剂量学的步骤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This work aimed at estimating the kinetic parameters, and hence cumulated activity (AC), of a diagnostic/therapeutic convergence radiopharmaceutical, namely 64Cu-/177Lu-labeled antibody (64Cu-/177Lu-cetuximab), that acts as anti-epidermal growth factor receptor. Methods: In mice bearing esophageal squamous cell carcinoma tumors, to estimate uptake (K), release rate constant (kR), and hence AC, a kinetic model analysis was applied to recently published biodistribution data of immuno-PET imaging with 64Cu-cetuximab and of small-animal SPECT/CT imaging with 177Lu-cetuximab, including blood and TE-8 tumor. Results: K, kR, and AC were estimated to be 0.0566/0.0593 g⋅h-1⋅g-1, 0.0150/0.0030 h-1, and 2.3 × 1010/4.1 × 1012 disintegrations (per gram of TE-8 tumor), with an injected activity of 3.70/12.95 MBq, for 64Cu-/177Lu-cetuximab, respectively. Conclusion: A model is available for comparing kinetic parameters and AC of the companion diagnostic/therapeutic 64Cu-/177Lu-cetuximab that may be considered as a step for determining whether one can really use the former to predict dosimetry of the latter.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Laffon E, Thumerel M, Jougon J, et al. Cumulated Activity Comparison of 64Cu-/177Lu-Labeled Anti-Epidermal Growth Factor Receptor Antibody in Esophageal Squamous Cell Carcinoma Model. J Nucl Med. 2017. PMID: 28082435. doi:10.2967/jnumed.116.180521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。